MDxHealth tags Miraca as promotion partner
HERSTAL, Belgium—Molecular diagnostic company MDxHealth SA has struck an agreement with Irvine, Calif.-based Miraca Life Sciences for the promotion of MDxHealth’s ConfirmMDx for Prostate Cancer test. More than 975,000 American men receive negative prostate biopsy results each year, yet because a biopsy sampling represents less than 1 percent of a man’s prostate, roughly 25 percent of those men could still harbor occult prostate cancer. The test is an epigenetic assay that aids urologists in determining which patients have a true negative biopsy and which are at risk for undetected cancer. No financial details were disclosed.
“Through this strategic partnership with MDxHealth, we can now offer a well-validated epigenetic assay which delivers new molecular insights on a patient’s risk for undetected cancer, thereby enabling our clients to make more informed decisions about the need for a repeat prostate biopsy,” said Dr. Frank Basile, president and CEO of Miraca.